Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.17 EUR -4.41%
Market Cap: 101.1m EUR
Have any thoughts about
Heidelberg Pharma AG?
Write Note

Heidelberg Pharma AG
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Heidelberg Pharma AG
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Heidelberg Pharma AG
XETRA:HPHA
Revenue
€9.9m
CAGR 3-Years
5%
CAGR 5-Years
22%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Revenue
€3.8B
CAGR 3-Years
99%
CAGR 5-Years
97%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Revenue
€203.5m
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
10%
Immatics NV
NASDAQ:IMTX
Revenue
€54m
CAGR 3-Years
20%
CAGR 5-Years
70%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Revenue
€707m
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
3%
Formycon AG
XETRA:FYB
Revenue
€77.7m
CAGR 3-Years
31%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Heidelberg Pharma AG
Glance View

Market Cap
101.1m EUR
Industry
Biotechnology

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

HPHA Intrinsic Value
2.61 EUR
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Heidelberg Pharma AG's Revenue?
Revenue
9.9m EUR

Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Revenue amounts to 9.9m EUR.

What is Heidelberg Pharma AG's Revenue growth rate?
Revenue CAGR 5Y
22%

Over the last year, the Revenue growth was -47%. The average annual Revenue growth rates for Heidelberg Pharma AG have been 5% over the past three years , 22% over the past five years .

Back to Top